Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression
Authors' conclusion
Our integrated analyses identified novel circulating protein markers associated with disease progression in MEN1-related dpNET.
Study context
- Population
- Patients with MEN1 (MD Anderson Cancer Center, National Institutes of Health, University Medical Center Utrecht); findings compared with serial plasmas from Men1fl/flPdx1-CreTg mice and Men1fl/fl control mice
- Participants
- 56 patients
- Comparison
- MEN1 patients with distant metastatic duodenopancreatic neuroendocrine tumors (dpNETs) vs indolent or no dpNETs
- Casesn = 14
- Controlsn = 42reference
- Outcome
- Circulating proteins associated with distant metastasis
Methodological detailsmass spectrometry-based proteomic profiling, international collaboration, plasma-based
- Mass spectrometry-based proteomic profiling
- International collaboration
- Plasma-based
Main finding
As reported in the abstract
Proteins elevated in MEN1 patients with distant metastasis vs controls, incl. 9 previously associated with pancreatic cancer and other neuronal proteins
187
Proteins associated with disease progression in Men1fl/flPdx1-CreTg mice, enriched for transcriptional targets of oncogenic MYCN, YAP1, POU5F1 and SMAD
196
Proteins positively associated with disease progression in both human patients and Men1fl/flPdx1-CreTg mice
19
Observational data: associations, not effects.
Original publication
Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab. Published 12 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →